What were the most popular posts on Healthcare Economist this year? Here are the top 10 in descending order:

1. Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
2. The world is relying on the United States to get value-based drug pricing right
3. Why is the market design for innovative pharmaceuticals not well understood?
4. Requiem for odds ratios?
5. Challenges in Conducting Economic Evaluations for Orphan Drugs in Rare Diseases
6. Which econometric method should you use for health policy causal inference?
7. Does NICE consider real-world data (RWD) for HTA evaluations?
8. Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?
9. Daron Acemoglu, Simon Johnson and James Robinson win 2024 Nobel Prize in Economics
10. The Carer QALY Trap

Other articles high on the popularity list, but which fell just outside the top 10 include: “What is HEMA?“, “Will ICER’s ‘shared savings’ approach decrease value-based prices most for the most severe diseases?” and “Do Treatment Sequencing / Pathways Models Have a Place in Health Technology Assessment?“

If you missed any of these, feel free to take some to review any that sound interesting to you.

Of note, 2025 will mark my 20th year of blogging nearly every weekday. I started the blog January 19, 2006 with the wholly original post “Welcome!” and have written over 5,500 articles since. I look forward to writing posts for this blog for at least another 20 years to come.